Analytical Data
-
Gene name
Siglec-10
- Application
-
Alternative Names
SIGLEC10; MGC126774; PRO940; Siglec10; SLG2
-
Species
Cynomolgus
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A2K5WBX8
-
Expression Region
T17-A549
-
Molecular Weight
80-90 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-10 is a member of the Siglec (sialic acid-binding immunoglobulin-like lectin) family, which plays a crucial role in the immune system by recognizing sialic acid-containing glycoproteins and glycolipids. It is primarily expressed on immune cells, particularly in myeloid lineage, and is implicated in the regulation of immune responses, including the modulation of inflammation and the attenuation of autoimmune diseases. Research has shown that Siglec-10 can inhibit the activation of immune cells, such as macrophages and dendritic cells, thereby maintaining immune homeostasis. The significance of Siglec-10 in various pathological conditions, including cancer, has sparked interest in the development of therapeutic strategies targeting this molecule. Recombinant Siglec-10 proteins have been generated for studying its structure and function, allowing researchers to explore its potential as a biomarker for disease diagnosis and as a target for immunotherapies. Understanding the mechanisms by which Siglec-10 interacts with its ligands can provide insights into its role in health and disease, paving the way for novel treatment approaches that leverage its immune-regulatory functions. This growing body of research emphasizes the importance of characterizing Siglec-10, particularly in the context of its contributions to immune regulation, making it a promising area for future biomedical investigation.
